



OmicsX
innovation INSIGHTS

14TH Edition

Global
**Oncology Preclinical
Drug Intelligence
2024**

*Complete Insights on
1250 Early Stage Drug Developers*

© Technologies © Pipeline © Funding © Deals

WORLD'S LARGEST COVERAGE - GUARANTEED

Disclaimer

At the time of creation of this report, all information present herein was known to be true and accurate, to the best knowledge of creators. HH BioTechnologies accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without warranty, and HH BioTechnologies makes no representation of warranty of any kind as to the accuracy or completeness of any information here to contained.

ISBN 978 81 926399 0 4

ISBN 978-81-926399-0-4

© April 2024 by HH BioTechnologies Pvt. Ltd. All rights reserved.

All information contained in this publication is copyrighted in the name of HH BioTechnologies Pvt. Ltd., and no part of this publication may be reproduced, resold, redistributed, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopying, scanning, or otherwise—without prior written permission of the publisher.

Permissions may be sought directly from HH Biotechnologies' through an email at reports@omicsx.com


OTHER REPORT IN THIS SERIES -

GLOBAL ONCOLOGY CLINICAL DRUG INTELLIGENCE **2024** World's Largest Active Resource for Decision Making

*Complete Insights on
1250 Clinical Stage Drug Developers*

© Technologies © Pipeline © Funding © Deals

Contents



Introduction 5

Table of Contents 6

List of 1250 Active Preclinical Stage Oncology Drug Developers..... 11

Section A

Global Oncology Preclinical Drug Developers - 2024 29
Summary on 1250 Active Preclinical Stage Drug Developers

- **Quantitative Estimation of Preclinical Oncology Companies present in United States vs. Europe vs. Asia vs. Canada vs. Rest of the World.** 30
- **Distribution of 1250 Preclinical Oncology Drug Developers, on the basis of Year of Establishment.** 30
 Explore the Emergence of Cancer Drug Discovery & Development.
- **Country-wise Distribution of Preclinical Oncology Drug Developers with Cancer Drug Development Program in Europe & Asia Region.** 31
 Identify Countries Supporting Cancer Drug Development around the Globe.
- **State-wise Distribution of Preclinical Oncology Drug Developers having Active Cancer Drug Development Program in United States of America** 31
 Explore the Key Oncology Research supporting States in United States.

Infographics

Oncology Drug Development Landscape - 2024	32
<i>Complete Insights on Early Stage Oncology Drug Development</i>	
97 □ Oncology Preclinical Stage Drug Developers Developing Small Molecule Kinase Inhibitors Cancer Targeting Drugs.	32
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
59 □ Oncology Preclinical Stage Drug Developers Developing Small Molecule Targeted Protein Degraders	37
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
24 □ Oncology Preclinical Stage Drug Developers Developing Cancer Targeting Radiopharmaceuticals.	41
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
32 □ Oncology Preclinical Stage Drug Developers Developing Oncolytic Virus Based Cancer Targeting Drugs.	43
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
172 □ Oncology Preclinical Stage Drug Developers Developing Cellular Therapies - CAR-T / CAR-NK & other Cell based Therapies.	45
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
152 □ Oncology Preclinical Stage Drug Developers Developing Cancer Targeting Monoclonal Antibodies against Tumor Antigen.	54
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
62 □ Oncology Preclinical Stage Drug Developers Developing Bispecific Antibodies & Bispecific T Cell Engagers.	62
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
68 □ Oncology Preclinical Stage Drug Developers Developing Antibody Drug Conjugates.	66
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
84 □ Oncology Preclinical Stage Drug Developers Developing Cancer Vaccines.	70
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
20 □ Oncology Preclinical Stage Drug Developers Developing Exosome & Microvesicles Based Cancer Targeting Drugs.	75
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	
28 □ Oncology Preclinical Drug Developers Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs.	77
<i>Companies Intelligence Snapshot covering Companies, Technologies & Molecules in Development.</i>	

Oncology Drug Funding 79

Complete Insights on Early Stage Venture Drug Funding

- 118** □ **Oncology Early Stage Drug Development Companies** 79

Private Financing in 2023

Insights on Onco Drug Developers who raised Funds through Private Financing in 2023

□
- 529** □ **Angel / Venture Investors Invested in Oncology Early Stage** 85

Drug Development Companies During 2022-23

Insights on Onco *Investors and their oncology portfolio companies.*

□

Oncology Drug Development Deals & Alliances 118

Insights on Early Stage Oncology Drug Development Deals

- **Early Stage Oncology Drug Development Companies** 118

Major Business Deals

Pre-build Intelligence on Early Stage Oncology Drug Developers Deals in 2023

□
- **Early Stage Oncology Drug Development Companies Research** 125

Collaboration with Non Profit Organizations

Pre-build Intelligence on Early Stage Oncology Drug Developers Deals in 2023.

□
- **CRO / Service Providers and Early Stage Oncology Drug Developers,** 127

Collaborations & Deals

Pre-build Intelligence on Early Stage Oncology Drug Developers Deals in 2023.

□

Special Coverage

- 148** □ **Oncology Preclinical Drug Developers** 128

Entering First in Cancer Clinical Trials in 2024

Intelligence Snapshot covering Companies Entering Clinic in 2024

□

Section B

134

□ *Individual Profiles of 1250 Active Oncology Preclinical Stage Drug Developer Companies*

Individual Drug Developer Profile includes:

Company Overview, Key Technology Platform, Venture Funding Rounds, Oncology centered Deals & Partnership, Collaborations and Business Insights.

Oncology Preclinical Drug Pipeline –Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMEA Orphan drug status.

Management Profile –Address, Contact number, e-mail, Key Management / Decision Maker (CXOs) name and designation, with individual Linked ID and contact emails.

Appendix A: List of 1250 Oncology Preclinical Drug Development Companies..... 945

ASIA	<i>Companies Present in China</i>
	<i>Companies Present in India</i>
	<i>Companies Present in Israel</i>
	<i>Companies Present in Japan</i>
	<i>Companies Present in Singapore</i>
	<i>Companies Present in South Korea</i>
	<i>Companies Present in Taiwan</i>
EUROPE	<i>Companies Present in Austria</i>
	<i>Companies Present in Belgium</i>
	<i>Companies Present in Bulgaria</i>
	<i>Companies Present in Denmark</i>
	<i>Companies Present in Finland</i>
	<i>Companies Present in France</i>
	<i>Companies Present in Germany</i>
	<i>Companies Present in Hungary</i>
	<i>Companies Present in Ireland</i>
	<i>Companies Present in Italy</i>
	<i>Companies Present in Lithuania</i>
	<i>Companies Present in Netherlands</i>
	<i>Companies Present in Norway</i>
	<i>Companies Present in Poland</i>
	<i>Companies Present in Portugal</i>
	<i>Companies Present in Spain</i>
<i>Companies Present in Sweden</i>	
<i>Companies Present in Switzerland</i>	
<i>Companies Present in United Kingdom</i>	

NORTH AMERICA***United States***

Companies Present in Alaska
Companies Present in Arizona
Companies Present in California
Companies Present in Colorado
Companies Present in Connecticut
Companies Present in Delaware
Companies Present in Florida
Companies Present in Georgia
Companies Present in Iowa
Companies Present in Illinois
Companies Present in Indiana
Companies Present in Louisiana
Companies Present in Maryland
Companies Present in Massachusetts
Companies Present in Michigan
Companies Present in Minnesota
Companies Present in Mississippi
Companies Present in Missouri
Companies Present in Montana
Companies Present in New Hampshire
Companies Present in New Jersey
Companies Present in New Mexico
Companies Present in New York
Companies Present in North Carolina
Companies Present in Ohio
Companies Present in Oregon
Companies Present in Pennsylvania
Companies Present in Rhode Island
Companies Present in South Carolina
Companies Present in Texas
Companies Present in Utah
Companies Present in Virginia
Companies Present in Washington
Companies Present in Wisconsin

Companies Present in Canada

SOUTH AMERICA

Companies Present in Argentina
Companies Present in Costa Rica
Companies Present in Puerto Rico

AUSTRALIA

Companies Present in Australia
Companies Present in New Zealand

List of Companies

Pre-Clinical Stage Cancer Drug Developers

1E Therapeutics Ltd.	135	ABBA Therapeutics AG	149
3B Pharmaceuticals GmbH	136	Abcely SAS	150
20Med Therapeutics B.V.	137	Abdera Therapeutics, Inc.	151
20n Bio, Inc.	137	Abera Bioscience AB	152
21st Century Therapeutics, Inc.	138	Abilita Therapeutics, Inc.	152
76Bio, Inc.	138	Ability Biologics, Inc.	153
280Bio, Inc.	139	Abintus Bio, Inc.	153
3T Biosciences, Inc.	140	AbLeads	154
4C Biomed, Inc.	141	Abologix Sàrl	154
4HF Biotec GmbH	141	Abpro Corporation	155
4Cell Therapies S.A.	142	Absolve Therapeutics, Inc.	156
858 Therapeutics, Inc.	143	AbTis Co, Ltd.	156
A2i Therapeutics Ltd.	144	Abzyme Therapeutics, LLC	157
A-Alpha Bio, Inc.	145	AC Bioscience SA	158
Aakha Biologics, Inc.	146	Accent Therapeutics, Inc.	159
Aarvik Therapeutics, Inc.	146	Accession Therapeutics Ltd.	160
Aavocyte, Inc.	147	Accro Bioscience Co., Ltd.	160
Ab Therapeutics, Inc.	147	Accuronix Therapeutics, Inc.	161
Abacus Bioscience, Inc.	148	Aclys Bio Corp.	161
Abalone Bio, Inc.	148	ACM Biolabs Pte. Ltd.	162
Abalos Therapeutics GmbH	149	Actinobac Biomed, Inc.	162



Section A provides a Quick Synopsis to Companies working in the domain.

This preview copy contains Starting Companies from each section.

Later **Section B** Profiles Individual companies in details.

Section A

1250 PRECLINICAL STAGE
ONCOLOGY DRUG DEVELOPERS

INTELLIGENCE SNAPSHOT

ONCOLOGY DRUG DEVELOPMENT LANDSCAPE 2024

Oncology Preclinical Drug Developers Developing Small Molecule Kinase Inhibitors Cancer Targeting Drugs (97 companies)

Table No. A.1

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	280Bio, Inc.	2022	United States	280Bio is developing small molecule KRAS inhibitor, which blocks tumor progression and overcome KRASG12C inhibitor mediated resistance.
2.	4HF Biotec GmbH	2015	Germany	4HF Biotec is a bioinformatics and data analytics company developing small molecule kinase inhibitors.
3.	AGV Discovery SAS	2013	France	AGV Discovery is developing potent and selective small molecule ERK kinase inhibitors targeting advance cancers.
4.	Ajax Therapeutics, Inc.	2019	United States	Ajax is developing pipeline of novel small molecules kinase inhibitors targeting key cytokine signaling pathways that drive hematologic malignancies.
5.	Allinky Biopharma SL	2009	Spain	Allinky is developing a small molecule inhibitor of Ras protein.
6.	Angex Pharmaceutical, Inc.	2017	United States	Angex Pharmaceutical is developing small molecules heterocyclic compounds as PRMT5 and TRK Kinase inhibitors targeting solid tumors.
7.	Anji Onco, Inc.	2020	United States	Anji Onco is developing oral hematopoietic cell kinase (HCK) Inhibitors.
8.	Applied Therapeutics, Inc.	2016	United States	Applied Therapeutics' AT-104 is an oral selective PI3K Delta and Gamma inhibitor and is in preclinical development for primary B-cell malignancies and is expected to enter clinical trials in 2021.
9.	Arctoris Ltd	2016	United States	Arctoris is a AI platform company built on robotics, data science, and machine learning, and is building a small molecule pipeline of wholly-owned and partnered first-in-class therapeutics in oncology.
10.	Arjuna Therapeutics	2018	United States	Arjuna Therapeutics (formerly Nanogap Therapeutics) is developing small molecule inhibitor of KRAS protein.
11.	Arrien Pharmaceuticals LLC	2011	United States	Arrien Pharmaceuticals is developing small molecule inhibitor of the Salt Inducible Kinases 2 and 3 (SIK2, SIK3) and selective and brain penetrable small molecule inhibitor of Maternal Embryonic Leucine zipper Kinase (MELK), targeting cancer.
12.	Atomwise Inc.	2012	United States	Atomwise is an AI driven drug discovery company, developing a pipeline of small-molecule drug candidates based on the uses of deep learning for structure-based drug discovery.

Oncology Preclinical Stage Drug Developers Developing Targeted Protein Degraders (59 Companies)

Table No. A.2

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	76Bio, Inc.	2020	United States	76Bio (formerly TRC 2001) engineers highly specific targeted protein degradation (TPD) therapeutics for previously undruggable targets.
2.	A-Alpha Bio Inc	2017	United States	A-Alpha identify and characterize novel pairs of E3 ubiquitin ligases for potential design and development of molecular glues to induce targeted protein degradation.
3.	AevisBio Inc.	2018	Korea	Aevisbio focused on the cereblon-mediated targeted protein modulators and establishes Proteomics-based Degron Library (PDL) platform technology which facilitate the identification of drug targets and the data-driven drug design instead of the artificial guesses.
4.	Amphista Therapeutics Ltd	2017	United Kingdom	Amphista is developing proteolysis targeting chimeras, or PROTACs, designed to make the cell degrade harmful proteins to treat cancer. Amphista's platform is independent of traditional E3 ubiquitin ligases process and is developing potent bifunctional small molecules to augment the body's own processes to remove disease-associated proteins
5.	AnHorn ' Medicines Co., Ltd.	2020	Taiwan	AnHorn specialize in Targeted Protein Degradation, finding novel E3 ligases, and using AI & CADD technology in drug discovery.
6.	Apertor Pharmaceuticals, Inc.	2020	United States	Apertor Pharmaceuticals is an early stage biotech company developing novel molecular glues for therapeutic applications in oncology.
7.	ApoRx Biopharmaceuticals Ltd.	2021	Israel	ApoRx is focusing on the discovery, design, characterization, and development of small proteolysis targeting molecules (PTMs) against well-validated disease-causing proteins in cancer and other indications.
8.	Arrakis Therapeutics, Inc.	2015	United States	Arrakis Therapeutics is developing new class of "targeted RNA degraders" consists of small molecule drugs that selectively destroy RNAs encoding disease-causing proteins by inducing their proximity to nucleases.
9.	Asha Therapeutics LLC	2021	United States	Asha Therapeutics is developing small molecule protein degrader utilizing computational chemistry and medicinal chemistry utilizing its transformative precision drug design PRISM™ platform.

Oncology Preclinical Stage Drug Developers Developing Cancer Targeting RadioPharmaceuticals (24 companies)

Table No. A.4

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	3B Pharmaceuticals GmbH	2008	Germany	3B Pharmaceuticals has built a technology platform for developing a peptide targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP).
2.	Abdera Therapeutics, Inc.	2020	United States	Abdera Therapeutics is advancing a pipeline of antibody-based precision radiotherapeutics based on its proprietary ROVER™ platform.
3.	Akiram Therapeutics AB	2021	Sweden	Akiram Therapeutics is developing targeted radioimmunotherapy for anaplastic thyroid cancer, consisting of Akiram's proprietary antibody, in combination with the radioactive compound, Lutetium 177.
4.	Aktis Oncology, Inc.	2021	United States	Aktis Oncology is developing first-in-class alpha-emitting targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
5.	Alpha-9 Theranostics Inc.	2018	Canada	Alpha-9 Theranostics is a radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies.
6.	Bioptamers, Inc.	2018	United States	Bioptamers is a biotech start-up developing personalized aptamers based radio, chemo or immune precision therapies targeting cancer cells.
7.	C-Biomex Co., Ltd.	2017	Korea	CBiomex uses the PUS (Peptide-based Ultra-high-throughput Screening) platform, a peptide library high-speed screening technology to develop bio-radiopharmaceutical therapeutics (B-RPT), peptide-drug conjugates (PDC), etc.
8.	Coretag Therapeutics AG	2019	Switzerland	Coretag is developing targeted radiotherapies based on its proprietary Necrosis Targeting Platform Technology (NTPT), which uses selective cyanine dye that binds only when the cell membrane lost its integrity, as in case of cancer

Oncology Preclinical Drug Developers Developing Oncolytic Virus Based Cancer Targeting Drugs (32 Companies)

Table No. A.5

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	Abalos Therapeutics	2019	Germany	Abalos Therapeutics is developing oncolytic therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumor immune response.
2.	Accession Therapeutics Ltd.	2020	United Kingdom	Accession Therapeutics is developing genetically modified adenoviruses designed to carry a range of therapeutic payloads, that exclusively target cancer cells.
3.	AdCure Bio LLC	2016	United States	AdCure Bio is developing potent and safe immuno-stimulatory oncolytic viruses based therapies for the treatment of advanced solid tumors.
4.	Adze Biotechnology, Inc.	2019	United States	Adze Biotechnology is developing systemically deliverable oncolytic immunotherapies, cancer vaccines and PD-L1 decoy proteins in collaboration with the Mayo clinic.
5.	AmunBio, Inc.	2020	United States	AmunBio is developing and commercializing novel engineered immunotherapeutic oncolytic viruses for the treatment of hard-to-treat solid tumors and hematological malignancies.
6.	Bioarchitech Ltd	2017	United Kingdom	Bioarchitech is developing potent transgenes encoded vaccinia virus designed to prime anti-tumor immune responses.
7.	Bionoxx Inc.	2016	South Korea	Bionoxx platform technology (OTS-400) is based on oncolytic vaccinia virus armed with transgene that provides safety margin when added with myeloid modulation technology.
8.	CanVirex AG	2017	Switzerland	CanVirex's Oncolytic Measles Virus Platform is designed for the destruction of cancer cells, and Tumor-restricted delivery of immune modulating encoded transgenes.
9.				
10.				
11.				
12.				
13.				
14.				
15.				
16.				
17.				

Oncology Preclinical Stage Drug Developers Developing Cellular Therapies - CAR-T/CAR-NK & other Cell based Therapies (172 Companies) Table No. A 5

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	3T Biosciences	2017	United States	3T Biosciences is focusing on identification and validation of novel targets of T cell receptors for personalized therapy and is also developing TCR cell therapies against known and noble targets.
2	4Cell Therapies S.A.	2013	Poland	4Cell Therapies (formerly HELIX IMMUNO-ONCOLOGY S.A) is an early stage company developing CAR-T technologies based on its proprietary technologies.
3	Aavocyte, Inc.	2019	United States	Aavocyte focuses on developing various T cell immune therapy products to treat cancers based on its unique precise targeting rAAV delivery platform.
4	Abintus Bio, Inc.	2020	United States	Abintus therapies are based on the Abintus Modular Viral (retroviral) Platform (MVP), which have the potential to reprogram any cell type in the body and to target a range of diseases. The company's initial <i>in vivo</i> CAR-X products are designed to produce potent and durable immune responses against both hematologic malignancies and solid tumors.
5	Advesya SAS	2020	France	Advesya is a preclinical stage biotech company developing first-in-class CAR-T cell therapies, with an initial focus on acute myeloid leukaemia.
6	Affini-T Therapeutics Inc.	2021	United States	Affini-T Therapeutics is a venture-backed biotechnology company, advancing novel TCR-engineered T cell therapies for patients with hard-to-treat solid tumors.
7	Alaya.bio SAS	2022	France	Alaya.bio is advancing its proprietary <i>in situ</i> gene delivery platform based on polymeric delivery nanoparticle, particularly in the field of CAR T cell immunotherapy.

Oncology Preclinical Drug Developers Developing Cancer Targeting Monoclonal Antibodies (152 Companies)

Table No. A.6

NO.	COMPANY NAME	FOUND-ED YEAR	COUNTRY	MOLECULE NAME	TARGET	DEVELOPMENT STAGE	INDICATION	DESCRIPTION
1.	4C Biomed, Inc.	2016	United Kingdom	α4CB-1.1	TNFRSF14	Preclinical	Solid Tumors	Monoclonal Antibody
2.	Aakha Biologics, Inc.	2021	United States	UNDISCLOSED PIPELINE				Monoclonal Antibody
3.	Ab Therapeutics, Inc.	2019	United States	UNDISCLOSED PIPELINE				Monoclonal Antibody
4.	Abalone Bio, Inc.	2017	United States	UNDISCLOSED PIPELINE				Monoclonal Antibody
5.	ABBA Therapeutics AG	2016	Switzerland	ABBA19	Undisclosed	Preclinical	Lung Cancer Head & Neck Cancer	Monoclonal Antibody
6.	Abcely SAS	2022	France	ABC-101	Carcino-embryonic Antigen	Preclinical	Colorectal Cancer Lung Cancer GastroIntestinal Tract Cancers	Monoclonal Antibody
7.	Abilita Bio, Inc.	2014	United States	UNDISCLOSED PIPELINE				Monoclonal Antibody
8.	Ability Biologics, Inc.	2023	Canada	UNDISCLOSED PIPELINE				Monoclonal Antibody

Oncology Preclinical Drug Developers Developing Cancer Targeting Bi-Specific/Multi-Specific Antibodies (62 Companies) Table No. A.8

No.	COMPANY NAME	FOUNDED YEAR	COUNTRY	MOLECULE NAME	TARGET	DEVELOPMENT STAGE	INDICATION	DESCRIPTION
1.	Aakha Biologics, Inc.	2021	United States	UNDISCLOSED PIPELINE				Bispecific Antibody
2.	Ab Therapeutics, Inc.	2019	United States	UNDISCLOSED PIPELINE				Bispecific Antibody
3.	ABBA Therapeutics AG	2016	Switzerland	UNDISCLOSED PIPELINE				Bispecific Antibody
4.	Abpro Therapeutics	2008	United States	ABP 100	Her2, CD3	IND	Breast Cancer Gastrointestinal Cancer	Bispecific Antibody
				ABP 110	GPC3, CD3	Preclinical	Hepatocellular Carcinoma	Bispecific Antibody
				ABP 160	CD47, PD-L1	Preclinical	Solid Tumors	Bispecific Antibody
				ABP 150	Claudin18.2 / CD3	IND	Gastrointestinal Cancer	Bispecific Antibody
5.	Absolve Therapeutics, Inc.		United States	UNDISCLOSED PIPELINE				Bispecific Antibody
6.	Abzyme Therapeutics, LLC		United States	UNDISCLOSED PIPELINE				Bispecific Antibody
7.	Affivant Sciences GmbH	2020	Switzerland	AFVT-2101 / AFM32	folate receptor, CD16A	IND	Advanced Solid Tumours	Bispecific Antibody
8.	Amberstone Biosciences	2016	United States	ABS-101	CD3, Undisclosed	Preclinical	Solid Tumors	Bispecific Antibody

Oncology Preclinical Drug Developers Developing Cancer Targeting Antibody Drug Conjugates (68 Companies)

Table No. A.9

No.	COMPANY NAME	FOUNDED YEAR	COUNTRY	MOLECULE NAME	TARGET	DEVELOPMENT STAGE	INDICATION	DESCRIPTION
1.	Aarvik Therapeutics, Inc.	2020	United States	UNDISCLOSED PIPELINE				Antibody Drug Conjugate
2.	AbTis Co, Ltd.	2016	South Korea	UNDISCLOSED PIPELINE				Antibody Drug Conjugate
3.	ADCendo ApS	2017	Denmark	Undisclosed	uPARAP	Preclinical	Glioblastoma	Antibody Drug Conjugate
4.	Adcentrx Therapeutics, Inc.	2021	United States	UNDISCLOSED PIPELINE				Antibody Drug Conjugate
5.	Albatroz Therapeutics, Inc.	2020	Singapore	ALB-02	Calnexin	Discovery	Solid Tumors	Antibody Drug Conjugate
6.	Angiex, Inc.	2015	United States	AGX101	TM4SF1	IND	Solid Tumor	Antibody Drug Conjugate
7.	Antikor Biopharma Limited	2001	United Kingdom	ANT043	HER 2	Preclinical	Solid Tumor	Antibody Fragment Drug Conjugate
8.	Aphios Corporation	1993	United States	APH-0912		Preclinical	Metastatic Cancer	Antibody Drug Conjugate
9.	AprilBio Co Ltd.	2013	South Korea	APB-CS	Undisclosed	Discovery	Solid Tumors	Antibody Drug Conjugate
9.	Araris Biotech AG	2019	Switzerland	UNDISCLOSED PIPELINE				Antibody Drug Conjugate

Oncology Preclinical Stage Drug Developers Developing Cancer Vaccines (84 Companies)

Table No. A.10

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	MOLECULE NAME	TARGET	DEVELOPMENT STAGE	INDICATION	DESCRIPTION
1.	Abacus Biosciences Inc	2017	United States	UNDISCLOSED PIPELINE				Vaccine
2.	Abera Bioscience AB	2012	Sweden	Ab04	-	Discovery	Cancer	Vaccine
3.	Adze Biotechnology Inc	2019	United States	ADZ1.17.FA.4	4-1BB	Discovery	Solid Tumor	Vaccine
4.	AILSEVAX Limited	2021	United Kingdom	AVX101	-	Preclinical	Head & Neck Cancer	Vaccine
				AV-N007	-	Preclinical	Colorectal Cancer	Vaccine
5.	Akshaya Bio, Inc.	2010	Canada	Chimigen Cancer Vaccine	-	Discovery	Solid Tumors	Vaccine
6.	Altevac SAS	2016	France	MELITECH	-	Preclinical	Glioblastoma	Vaccine
7.	Annias Immunotherapeutics Inc.	2012	United States	PEP-CMV	CMV antigens	Preclinical	Glioblastoma multiformes	Vaccine
8.	AptaBio Therapeutics, Inc.	2009	South Korea	APV-224	NOX	Discovery	Liver Cancer	Peptide Vaccine
							Gastric Cancer	
9.	ARV Technologies, Inc.	2021	United States	ARV-2001	-	Preclinical	Cervical Cancer	mRNA Vaccine
10.	Attivare Therapeutics Inc	2020	United States	UNDISCLOSED PIPELINE				Vaccine

Oncology Preclinical Stage Drug Developers Developing Exosome & Micro-vesicles Based Cancer Targeting Drugs (20 Companies)

Table No. A.11

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	CaraVan Biologix, Inc.	2020	United States	CaraVan's allogeneic iPSC-derived mini-CAR™ and mini-VAN™ BioNanoVesicles (BioNVs) platforms, are based on Cell-Derived Vesicles (CDVs), which can be rapidly designed, engineered, and manufactured with superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions.
2.	Coastar Therapeutics, Inc.	2017	United States	Coastar Therapeutics' proprietary Erythrocyte Lipid Coating Vesicle, "ELCV" technology is utilized to coat biological payloads such as therapeutic viruses with a layer of cell membrane, which can shield the virus from immune system detection and clearance.
3.	Diadem Biotherapeutics, Inc.	2019	United States	Diadem's DECOSTAR™ immune checkpoint agonist extracellular vesicle platform Re-program bioprocessing cell lines to produce large quantities of extracellular vesicles with specific therapeutic messages, that mimic direct cell-to-cell communication, and overcomes the challenge of immune checkpoint agonism.
4.	EV Therapeutics, Inc.	2020	United States	EV Therapeutics is developing exosomes without immunosuppressive microRNAs, in combination with immune checkpoint inhibitors, as a novel combination therapy in preclinical models with advanced-stage colorectal cancer, which proved effective.
5.	Exollence Biotechnology Co., Ltd	2019	Korea	Exollence's SWEET™ (Shock Wave Exosome Engineering Technology) platform technology is designed for the production of target molecule-encapsulated exosome with high loading drug delivery efficiency using Extracorporeal Shock Wave (ESW).
6.	ExonanoRNA LLC	2017	United States	ExonanoRNA is preclinical stage nanotechnology company, developing exosomes-based drugs and innovative pharmaceuticals based on its unique RNA nanotechnology platform for next generation targeted drug delivery and disease diagnosis.

Preclinical Drug Developers Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs (28 companies)

Table No. A.12

NO.	COMPANY NAME	FOUNDED YEAR	COUNTRY	DESCRIPTION
1.	Actinobac Biomed Inc	2009	United States	Actinobac is developing Leukothera™, a bacterial protein derived from <i>Aggregatibacter actinomycetemcomitans</i> , that binds leukocyte function antigen (LFA-1) on white blood cells and induces cell death via apoptosis or necrosis.
2.	Actym Therapeutics	2017	United States	Actym's STACT (<i>S. Typhimurium</i> Attenuated Cancer Therapy) technology platform is designed to deliver genetic payload-encoding plasmid, which allows the expression of heterologous proteins in a tumor-specific manner, for the direct and persistent expression of a wide range of therapeutic immuno-modulatory factors in the tumor microenvironment.
3.	Ancilia Biosciences	2019	United States	Ancilia Biosciences is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome.
4.	Baccine LTD	2022	Israel	Baccine is developing bacteria-based immunotherapy treatment to enhance anti-tumor immunity and provide better treatment options.
5.	BacoCure Ltd.	2018	Israel	BacoCure is startup company developing a novel bacterial product as a local therapy (intravesicular) for non-muscle invasive bladder cancer (NMIBC) patients.
6.	Bio Palette Co., Ltd.	2017	Japan	Bio Palette is a microbiome company developing microbiome therapeutics by using bacteria optimized by CRISPR-Cas9 base editing to specifically modify and control microbiome without cutting DNA strands.
7.	BiomX Ltd.	2015	Israel	BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases.
8.	Eligo Bioscience S.A.	2014	France	Eligo Bioscience has designed GEM (Gene Editing of the Microbiome) platform, a first-in-class proprietary platform to edit the microbiome gene repertoire <i>in vivo</i> .

ONCOLOGY DRUG FUNDING LANDSCAPE

Oncology Early Stage Drug Development Companies - Private Financing

Table No. A.13

NO.	COMPANY NAME	COUNTRY	FUNDING AMOUNT	FUNDING ROUND	MONTH / YEAR	KEY INVESTORS IN THE ROUND
1.	A-Alpha Bio Inc	United States	\$22.4 Mn USD	Series A2	July 2023	Xontogeny Ventures, Madrona and other existing investors.
2.	Abacus Biosciences Inc	United States	\$4.4 Mn USD	Seed	Feb 2023	Washington Research Foundation, Pack Ventures, Lexandria Venture Investments.
3.	Abcely SAS	France	€2.4 Mn	Seed	Sep 2023	GO CAPITAL, Angels Santé, a major business angel, the Institut de Cancérologie de l'Ouest (ICO)
4.	Abdera Therapeutics, Inc.	United States	\$142 Mn USD	Series A & B	April 2023	Versant Ventures, Amplitude Ventures, Northview Ventures, venBio Partners, Viking Global Investors, Qiming Venture Partners USA and RTW Investments.
5.	Abera Bioscience AB	Sweden	£ 1.8 Mn	Grant	Nov 2023	UK Vaccine Network program, funded by the Department of Health and Social Care, U.K
6.	Abilita Bio, Inc.	United States	\$7.5 Mn USD	Undisclosed	Feb 2023	Two Bear Capital
7.	Ability Biologics, Inc.	Canada	\$12 Mn USD	Undisclosed	Dec 2023	Amplitude Ventures, Fonds de solidarité FTQ, Charles River Laboratories, Alexandria Venture Investments, Page One Ventures.
8.	Actym Therapeutics	United States	\$25.5 Mn USD	Series A (Extension)	Oct 2023	Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture.
9.	ADCendo ApS	Denmark	31 Mn EUR	Series A (Extension)	April 2023	Pontifax Venture Capital, Novo Holdings, Ysios Capital.
10	Adze Biotechnology, Inc.	United States	\$6.2 Mn USD	Series A1	March 2023	Undisclosed investors

Angel Investors / Venture Investors Invested in Oncology Early Stage Drug Development Companies (529 Investors)

Table No. A.14

NO.	INVESTOR NAME	COUNTRY	FUNDING STAGES	KEY PORTFOLIO (ONCOLOGY DRUG DEVELOPERS)
1	11.2 Capital www.112capital.com	United States	Seed	Noetik, Inc.
2	5Y Capital (formerly Morningside Venture) www.5ycap.com/en/	China	Seed	ReviR Therapeutics
3	3B Future Health Fund https://3bfuturehealth.com/	Europe	Series A, Series B	Domain Therapeutics SA, Sibylla Biotech S.r.l., EpsilonGen
4	3E Bioventures Capital www.3ebiovc.com/	United States	Series A Series C+	Larkspur Biosciences, Inc. Dewpoint Therapeutics Inc.
5	3ONE4 Capital India www.3one4capital.com/	India	Series B	Bugworks Research India Pvt. Ltd.
6	7G Bioventures https://7gventures.com/about-us/	United States	Series A	KAYOTHERA Inc
7	8VC https://www.8vc.com/	United States	Series A, Series B	Mantra Bio, Inc. Hexagon Bio, Inc. hC Bioscience Dren Bio, Inc.
8	Abingworth www.abingworth.com	United Kingdom	Series B	Iambic Therapeutics, Inc.
9	Accelerator Life Science Partners www.acceleratorlsp.com/	United States	Series A	KAYOTHERA Inc.
10	Access Industries www.accessindustries.com/	United States	Series A	Treeline Biosciences, Inc.
11	Acequia Capital www.acecap.com	United States	Seed	Valink Therapeutics (LiliumX Ltd.)
12	Acorn Bioventures www.acornbioventures.com/	United States	Series A, Series B, Series C+	ONK Therapeutics Limited
13	Acquipharma Holdings S.A	South Africa	Series B	Bugworks Research India Pvt. Ltd.
14	Adjuvant Capital https://adjuvantcapital.com/	United States	Series B	Memo Therapeutics AG
15	adMare BioInnovations https://www.admarebio.com/en/	Canada	Series A	Domain Therapeutics SA
16	Advantage Capital (Ironwood) www.advantagecap.com	United States	Seed	Modifi Biosciences, Inc.
17	Advent Life Sciences https://adventls.com/	United Kingdom	Seed, Series A	Epitopea Ltd., PIC Therapeutics, Inc.
18	Affinity Asset Advisors https://affinityadv.com/	United States	Series A	Ceptur Therapeutics, Inc.
19	Agent Capital https://www.agentcapital.com/	United States	Series C+	ImCheck Therapeutics SAS Vittoria Biotherapeutics, Inc.
20	AIHC Fund https://www.aihccapital.com/home	China	Series B	InxMed (Shanghai) Co., Ltd.

ONCOLOGY DRUG DEVELOPMENT DEALS

Early Stage Oncology Drug Development Companies Major Business Deals & Collaborations.

Table No. A.15

NO.	EARLY STAGE ONCO DRUG DEVELOPER	PARTNER COMPANY	DEAL SIZE	MONTH	DESCRIPTION
1.	3B Pharmaceuticals GmbH	RefleXion Medical	Undisclosed	Sep 2023	RefleXion Medical, Inc., acquired Global Rights to 3BP-4768 (now RXM-4768) a FAP targeting radiopharmaceutical molecule from 3B Pharmaceuticals to treat high unmet need cancers including brain, pancreatic and liver cancer. Financial details remains undisclosed.
2.	3B Pharmaceuticals GmbH	Novartis Innovative Therapies AG	\$425 Mn USD	April 2023	3BP granted Novartis Innovative Therapies AG, an exclusive worldwide rights to develop and commercialize therapeutic and imaging applications for 3BP's FAP-targeting peptide technology, including FAP-2286. FAP-2286 targets fibroblast activation protein (FAP), a promising theranostic target with expression across a majority of cancers. Under the terms, 3BP receives an initial payment of \$40 Mn as well as up to \$425 Mn in development, regulatory, and commercial milestone payments, in addition to tiered royalties on net sales.
3.	3T Biosciences	Boehringer Ingelheim	\$268 Mn USD	Jan 2023	Boehringer Ingelheim and 3T Biosciences signed licensing agreement to discover and develop next-generation cancer immunotherapies by utilizing 3T Biosciences' 3T-TRACE discovery platform. Under the terms, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T's target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, pre-clinical, clinical, regulatory, and commercial milestones totaling \$268 million in addition to royalties on future Boehringer Ingelheim product sales.
4.	Adecto Pharmaceuticals, Inc.	Duality Biologics		Jan 2023	Adecto signed an agreement with Duality Biologics to license Duality's proprietary, industry leading DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload platform for its lead uPARAP-ADC program in mesenchymal cancers.

Early Stage Oncology Drug Development Companies Research Collaboration with Non Profit Organizations

Table No. A.16

NO.	EARLY STAGE ONCO DRUG DEVELOPER	PARTNER COMPANY	MONTH	DESCRIPTION
1.	BCN Biosciences LLC	BARDA	Sep 2023	BARDA signed a cooperative agreement with BCN to evaluate the proof-of-concept studies of Yel002 on radiation damage prevention.
2.	Beactica AB	The National Center for Advancing Translational Sciences	Sep 2023	Beactica Therapeutics signed research collaboration with the National Center for Advancing Translational Sciences (NCATS), to evaluate Beactica's proprietary targeted TEAD degraders efficacy in disease-relevant preclinical models. NCATS will also map systematically the drug-combination landscape for selected preclinical candidates by performing a high-throughput drug-combination screen.
3.	C-Biomex Co., Ltd.	Korea Institute of Atomic Energy Medicine	June 2023	CBiomex and the Korea Institute of Atomic Energy Medicine signed a joint research agreement for the research and development of a number of innovative radioactive anticancer drugs, including CBT-001 (radioactive kidney cancer treatment).
4.	Cell BioEngines, Inc.	Icahn School of Medicine at Mount Sinai	Jan 2023	Cell BioEngines entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai to utilize Icahn Mount Sinai's technology platform to develop discrete immune cell-based therapies, such as subtypes of dendritic cells (DC), NK cells, and macrophages, previously inaccessible to cancer patients.
5.	FiLeClo sp. z o.o.	Medical Research Agency	Aug 2023	FiLeClo signed an agreement with the Medical Research Agency for co-financing of the FLC-436 clinical trials.
6.	Generate Biomedicine	Roswell Park Comprehensive Cancer Center	Nov 2023	Generate Biomedicines and Roswell Park Comprehensive Cancer Center signed a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, for up to three oncology targets, including in ovarian cancer and other solid tumors. The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park's expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.

Early Stage Oncology Drug Development Companies & CRO/BioSuppliers Major Business Deals

Table No. A.16

NO.	EARLY STAGE ONCO DRUG DEVELOPER	PARTNER COMPANY	MONTH	DESCRIPTION
1.	20Med Therapeutics	Touchlight	April 2023	20Med Therapeutics and Touchlight (a privately-owned UK based CDMO) collaborate to establish a novel vaccination platform that combines Touchlight's rapid enzymatic doggybone DNA platform with 20Med Therapeutics' bioresponsive polymer nanoparticle technology.
2.	Atavistik Bio Inc.	Plex Research	Jan 2023	Atavistik Bio sign collaboration with Plex Research to incorporate Plex Research's cloud-based AI-powered drug discovery search engine of large and disparate data sources to enrich the informatics capabilities of its Atavistik Metabolite Protein Screening (AMPS) platform and accelerate its drug discovery pipeline.
3.	Captor Therapeutics Inc	ICON	Oct 2023	Captor Therapeutics signed an agreement with ICON, to prepare and conduct the first phase of clinical trials of an innovative new anti-cancer drug under the CT-01 project.
4.	Catamaran Bio	OmniaBio, Inc.	March 2023	Catamaran Bio selects OmniaBio, Inc. (CDMO) as partner to develop and manufacture allogeneic CAR-NK cell therapies
5.	Cyclenium Pharma, Inc.	SpiroChem	June 2023	SpiroChem, a Switzerland based Contract Research Organization (CRO) acquired Cyclenium Pharma.
6.	InnDura Therapeutics, Inc.	Landmark Bio	June 2023	InnDura collaborates with Landmark Bio, a service providing company for the development and manufacturing of InnDura's pipeline products.

SPECIAL COVERAGE -

FIRST IN CANCER CLINICAL TRIALS - Preclinical Drug Developers which may Register for Clinical Studies in 2024 (148 companies)

Table No. A.17

NO.	COMPANY NAME	COUNTRY	MOLECULE NAME	TARGET	DEVELOPMENT STAGE	INDICATION	DESCRIPTION
1.	280Bio, Inc.	United States	TEB-17231 / YL-17231	KRAS	IND	KRAS-mutated Cancer	Small Molecule
2.	858 Therapeutics, Inc.	United States	ETX-19477	PARG	IND	Advance Solid Tumors	Small Molecule
3.	Aavocyte Inc.	United States	AAVOT	-	IND	Prostate Cancer	Gene Therapy
4.	Abpro Therapeutics	United States	ABP 100	Her2, CD3	IND	Breast Cancer	Bispecific Antibody
			ABP 150	Claudin18.2 / CD3	IND	Gastrointestinal Cancer	Bispecific Antibody
5.	AC BioScience SA	Switzerland	ACB2003.4	Sphingosine 1-phosphate	IND	Advance Pancreatic cancer	Small Molecule
6.	Accent Therapeutics	United States	ATX968	DHX9	IND	Colorectal Cancer	Small Molecule
7.	Accession Therapeutics Ltd.	United Kingdom	Undisclosed		IND	Advanced Solid Tumors	Oncolytic Virus
8.	ACM Biolabs Pte. Ltd.	Singapore	ACM-005	CpG 7909	IND	Lung Cancer	Biological
9.	Actym Therapeutics	United States	ACTM-838		IND	Solid Tumor	Engineered Bacteria
10.	Aculeus Therapeutics Pty Ltd.	Australia	ACU-0943	STING	IND	Solid Tumors	Small Molecule
11.	ADCendo ApS	Denmark	Undisclosed	uPARAP	IND	Glioblastoma	Antibody Drug Conjugate

Section B

1250 PRECLINICAL STAGE
ONCOLOGY DRUG DEVELOPERS

PROFILES

A2i Therapeutics Ltd.

Cancer/Autoimmune Disorders

2 Ilan Ramon St. , 3rd Floor,
Ness Ziona, 7403635
Israel

www.a2i-tx.com
info@a2i-tx.com
+972-8-9553175

Founded: 2020
Employee: 1-10
Ownership: Private

HIGHLIGHTS

- ★ A2i Therapeutics Ltd. is a joint venture company established by FutuRx and Atomwise, A2i utilize Atomwise's AI platform, AtomNet® technology, to target ADAR1, a key protein involved in controlling the innate immune response,
- ★ In Dec 2020, A2i Therapeutics, secure an undisclosed seed funding from FutuRx (the Israeli Innovation Authority) and its investors to develop novel small molecule immuno-oncology agents.

ONCOLOGY PIPELINE

Name	Target	Phase	Indication	Molecule Type
Undisclosed	ADAR1	Discovery	Advance Solid Tumors	Small Molecule

- ★ A2i Therapeutics is developing small molecule inhibitors of adenosine deaminase acting on RNA 1 (ADAR1). ADAR1 is an enzyme that deaminates the nucleotide adenosine to inosine in double stranded RNA (dsRNA), thus making dsRNA molecules unstable. Elevated ADAR1 activity has been reported in some cancers, and potentially allows cancer cells to exploit its activity to evade immune detection.
- ★ A2i Therapeutics intends to initially target Non-Small Cell Lung Cancer (NSCLC) and triple-negative breast cancer (TNBC), as these tumors appear to be ADAR-dependent.

CORPORATE PROFILE

Oshik Segev, Chief Scientific Officer

oshik@a2i-tx.com

[Linked in](#) profile

A-Alpha Bio, Inc.

Diversified

2101 4th Avenue, Suite 500
Seattle, WA 98121,
United States

www.aalphabio.com
contact@aalphabio.com
+1 8584057116

Founded: 2017
Employee: 11-50
Ownership: Private

HIGHLIGHTS

- ★ A-Alpha Bio (spinout of the Institute for Protein Design at the University of Washington) is a preclinical stage synthetic biology company, which combines computational tools with yeast experiments to identify potentially therapeutic proteins.
- ★ A-Alpha Bio has developed a proprietary platform technologies - **AlphaSeq** and **AlphaBind**. **AlphaSeq** uses genetically engineered yeast cells to experimentally measure millions of protein-protein interaction affinities simultaneously at a library-on-library scale, generating enormous amounts of data to inform the discovery and development of potent, specific, and cross-reactive drugs. A-Alpha Bio holds a database of almost 500 million protein-protein interaction measurements. This feeds into **AlphaBind**, which uses machine learning to predict new protein sequences with desired binding properties. A-Alpha Bio's computational tools, AlphaSeq and AlphaBind, work together to measure and analyze protein-protein interactions.
- ★ In Aug 2022, A-Alpha Bio signed collaboration with Bristol Myers Squibb to discover Molecular Glue Targets for Protein Degradation. Under the terms, A-Alpha to identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of molecular glues to induce targeted protein degradation.
- ★ In 2022, Amgen collaborate with A-Alpha Bio to discover several weakly interacting ligase-target pairs between a list of Amgen's targets utilizing A-Alpha's proprietary library of E3 ubiquitin ligases.
- ★ In Dec 2021, Kymera Therapeutics, signed collaboration with A-Alpha Bio to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues. Under the terms, A-Alpha Bio will discover and characterize druggable interactions between a curated list of high-value targets and its library of E3 ligases that Kymera can use as an input to its Pegasus™ platform for the rational discovery and development of molecular glues. Kymera will have the option to take a license for up to two targets for further development. In return, A-Alpha Bio will receive upfront and research payments and be eligible for downstream milestones.
- ★ In July 2023, A-Alpha Bio raised \$22.4 Mn in Series A2 financing led by previous investor Perceptive Advisors Xontogeny Ventures, with strong support from Madrona and other existing investors.
- ★ Earlier in Sep 2021, A-Alpha Bio raised \$20 Mn in Series A Financing led by Madrona Venture Group, accompanied by new investors Xontogeny and Lux Capital.

ONCOLOGY PIPELINE

Name	Target	Phase	Indication	Molecule Type
AAB-001	AATM28	Preclinical	Advance Solid Tumor	Small Molecule

CORPORATE PROFILE

Padma Kodukula, Chief Business Officer

[Linked in profile](#)

David Younger, Co-Founder and CEO

[Linked in profile](#)

Contact Us

reports@omicsx.com

2760 Link Road, Industrial Area,
AGRA 282006, INDIA

Phone : (+91) 562 2970444

Mobile : (+91) 9760 241 412

Website : www.omicsx.com